Get the Daily Brief
Latest Biotech News
Qiagen draws buyout interest — shares jump on sale chatter
Qiagen’s stock jumped as much as 20% after Bloomberg reported the company is exploring a potential sale and is in talks with advisers and suitors. Market commentary named Danaher and Agilent among...
Guardant and Merck partner on companion diagnostics — liquid biopsy tie‑up
Guardant Health and Merck struck a multi‑year collaboration to use Guardant’s portfolio of liquid and tissue biopsy tests to support patient enrollment in Merck’s global clinical studies. The deal...
Novo exits cell therapy bets — Aspect acquires diabetes assets
Novo Nordisk transferred rights to its stem‑cell derived islet and hypoimmune cell engineering technologies to Aspect Biosystems as part of a deal that lets Aspect develop the diabetes...
GSK snaps up Rapt for food-allergy antibody — $2.2B deal
GSK agreed to acquire Rapt Therapeutics for $2.2 billion to gain ozureprubart, a mid‑phase anti‑IgE antibody intended to prevent food-allergy reactions. The British drugmaker will pay $58 per...
Merck‑Moderna vaccine benefit endures — 5‑year melanoma data
Five‑year follow‑up shows the investigational Merck and Moderna therapeutic cancer vaccine maintained a 49% reduction in risk of recurrence or death when added to Merck’s anti‑PD‑1 therapy,...
FDA flexibility helps Beam push base editor toward accelerated path
Beam Therapeutics gained agency agreement to use a biomarker‑based endpoint evaluated over one year to support an accelerated approval filing for BEAM‑302 in alpha‑1 antitrypsin deficiency (AATD)....
Illumina wins CMS reimbursement — broadens access to CGP
The Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at $2,989.55 per test under PLA code 0543U, effective Jan. 1, 2026. The CMS...
Congress advances Medicare pathway for multi‑cancer early detection
Language in the federal appropriations bill would allow Medicare coverage of FDA‑approved multi‑cancer early detection (MCED) tests without waiting for U.S. Preventive Services Task Force...
Insilico splits rights on brain‑penetrant NLRP3 inhibitor — $66M accord
Insilico Medicine agreed to a deal that splits rights for a preclinical, brain‑penetrant NLRP3 inhibitor, securing a $10 million upfront from a newly formed Chinese biotech and setting up a...
Guardant and Merck partner on liquid and tissue companion diagnostics
Guardant Health and Merck launched a multi‑year collaboration to use Guardant’s liquid and tissue biopsy assays to support patient enrollment across Merck’s global clinical trials. The deal ties...
Exciva raises €51M to fund Alzheimer’s agitation pivotal program
Exciva GmbH closed a €51 million (US$59.9 million) Series B to finance a Phase II/III trial of Deraphan, a combination therapy for agitation in Alzheimer’s disease. The Heidelberg‑based...
Astellas relaunches XLMTM gene therapy with MyoAAV capsid program
Astellas Gene Therapies licensed KT430 (ASP2957), a MyoAAV capsid‑based gene therapy developed by Kate Therapeutics/Novartis, to re‑enter X‑linked myotubular myopathy (XLMTM) development with a...
Valneva withdraws chikungunya vaccine from U.S. after FDA concerns
Valneva voluntarily withdrew its chikungunya vaccine’s U.S. application and stopped a halted post‑marketing study after learning the FDA placed a clinical hold tied to a newly reported serious...
GSK buys Rapt for $2.2B – adds long‑acting anti‑IgE
GSK agreed to acquire Rapt Therapeutics for $2.2 billion, securing ozureprubart, a long‑acting anti‑IgE monoclonal antibody in Phase IIb development for prophylactic protection against food...
Boston Scientific buys Penumbra in $14.5B deal – expands thrombectomy portfolio
Boston Scientific announced a $14.5 billion cash‑and‑stock acquisition of Penumbra, bringing mechanical thrombectomy, embolization and neurovascular devices into Boston Scientific’s cardiovascular...
CMS reimburses Illumina oncology test – $2,989 rate opens precision‑oncology access
The U.S. Centers for Medicare & Medicaid Services granted reimbursement for Illumina’s TruSight Oncology Comprehensive assay at a rate of $2,989.55 per test, effective Jan. 1, 2026. The...
Merck‑Moderna vaccine sustains 49% melanoma risk cut at 5 years
Five‑year follow‑up data show that a therapeutic vaccine co‑developed by Merck and Moderna, when added to Keytruda (pembrolizumab), maintained a roughly 49% reduction in risk of recurrence or...
Astellas relaunches XLMTM gene therapy effort with MyoAAV capsid
Astellas Gene Therapies announced a partnership and exclusive license with Kate Therapeutics/Novartis assets to develop ASP2957 (MyoAAV3.8‑MHCK7‑hMTM1), a MyoAAV capsid‑based gene therapy for...
Valneva withdraws U.S. chikungunya shot amid FDA safety probe
Valneva voluntarily withdrew its chikungunya vaccine application and suspended a post‑marketing study in the U.S. after learning the FDA placed the product on clinical hold linked to a newly...
Parse and Graph build immune perturbation atlas – single‑cell scale
Parse Biosciences and Graph Therapeutics struck a strategic partnership to create a large‑scale immune cell perturbation atlas using Parse’s GigaLab single‑cell sequencing and Graph’s...